Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
Helus Pharma added Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, bolstering its translational science and clinical development expertise. The company highlighted its pipeline progress, including HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder.
Key figures
- Drug Name
- HLP003, HLP004
- Phase Of Trial
- Phase 3, Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.